Arca
Skip to content
Tools
Tools

Thyroid cancer

Drug research and approvals for thyroid cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 205 studies of thyroid cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 12 approved and 6 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 205
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 12
  • EU medicines: 2

Recruiting now

Newest posted first, of 205 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 9

Phase 3 11

Phase 2 12 of 65

Phase 1 or earlier 12 of 19

How its trials ended

749 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 127 whose ending is known, 35% met their primary endpoint, 12% missed it and 53% stopped early.

  • Ongoing26335%
  • Completed, result not reported23231%
  • Status unknown12717%
  • Met its primary endpoint456%
  • Stopped: other or unclear345%
  • Missed its primary endpoint152%
  • Stopped: enrollment or feasibility142%
  • Stopped: lack of efficacy81%
  • Stopped: funding51%
  • Stopped: sponsor or business decision41%
  • Stopped: safety2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Apr 26, 2023Study of talazoparib for metastatic relapsed settle tumour: a pediatric oncology precision medicine studyTalazoparibC17 CouncilClosed
Apr 13, 2022A phase III, randomized, open-label, study of pralsetinib versus standard of care for treatment of ret-mutated medullary thyroid cancer (acceleret mtc)Pralsetinib (RO7499790)/ Vandetanib/ CabozantinibRochePending
Aug 26, 2021A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients…Dabrafenib (DRB436) / Trametinib (TMT212)Novartis PharmaceuticalsOngoing
Feb 7, 2020A multicenter, randomized, open-label, phase 3 trial comparing selpercatinib to physicians choice of cabozantinib or vandetanib in patients with progressive,…Selpercatinib (LY3527723) / Cabozantinib / VandetanibEli LillyOngoing
Feb 19, 2019A phase 3, randomized, double-blind, placebo-controlled study of cabozantinib (XL184) in subjects with radioiodine-refractory differentiated thyroid cancer who…Cabozantinib / Technetium tc 99MExelixisClosed
Dec 14, 2018A phase 1/2 study of oral loxo 292 in patients with advanced solid tumors, including ret fusion-positive solid tumors, medullary thyroid cancer and other…Selpercatinib (LOXO-292)Eli LillyOngoing
Nov 23, 2017A phase I dose escalation trial to determine if imatinib treatment restores sodium iodide symporter function and sensitivity to radioiodine treatment in…ImatinibCross Cancer Institute - Cancer Care AlbertaOngoing
Oct 25, 2017A randomized, double-blind study to evaluate the efficacy and safety of cabozantinib (XLL84) at 60 mg/day compared to 140 mg/day in progressive, metastatic…CabozantinibExelixisClosed
Mar 8, 2016A multicenter, randomized, double-blind phase 2 trial of lenvatinib (E7080) in subjects with 131i-refractory differentiated thyroid cancer to evaluate whether…Lenvatinib (E7080)EisaiClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 18
May 29, 2024RetevmoTreatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET…Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Sep 17, 2021CabometyxTreatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC)…Exelixis, Inc.Approved
Dec 1, 2020GavretoTreatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer…Rigel Pharmaceuticals, Inc.Approved
May 8, 2020RetevmoRETEVMO is indicated for the treatment of: ¿ Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant…Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
May 4, 2018Tafinlar(r) Capsules a nd Mekinist(r) TabletsMEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid…Novartis Pharmaceuticals CorporationApproved
May 4, 2018Tafinlar(r) Capsules a nd Mekinist(r) TabletsTAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid…Novartis Pharmaceuticals CorporationApproved
Feb 13, 2015LenvimaTreatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancerEisai, Inc.Approved
Nov 22, 2013NexavarTreatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to…Bayer HealthCare Pharmaceuticals, Inc.Approved
Nov 29, 2012CometriqTreatment of progressive, metastatic medullary thyroid cancer (MTC).Exelixis, Inc.Approved
Apr 6, 2011CAPRELSA(r)Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic diseaseGenzyme CorporationApproved
Dec 14, 2007ThyrogenFor use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for…Genzyme CorporationApproved
Nov 30, 1998ThyrogenAs an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with…Genzyme CorporationApproved
Apr 21, 2020PentagastrinDiagnostic for the management of medullary thyroid cancerExela Pharma Sciences, LLCDesignated
Apr 9, 2019Autologous chimeric antigen receptor (CAR) T cells…Treatment of anaplastic thyroid cancer, medullary thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancerAffyImmune Therapeutics, Inc.Designated
Sep 2, 2011Ribavirin elaidateTreatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancerTranslational Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
Feb 16, 2012CaprelsaVandetanibEsteve Pharmaceuticals, S.A.EMA ↗
Mar 9, 2000ThyrogenThyrotropin alfaSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.